We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Empirical antibiotics of non-carbapenems for ESBL-producing E. coli and K. pneumoniae bacteremia in children : a retrospective medical record review
Summary
Researchers retrospectively analyzed clinical outcomes for 53 pediatric patients with ESBL-producing E. coli and K. pneumoniae bacteremia treated with carbapenem or non-carbapenem empirical antibiotics between 2014 and 2019. They found a 30-day all-cause mortality rate of 17%, with 84.6% of non-carbapenem-treated patients switched to carbapenem therapy by day 2, suggesting non-carbapenem empirical therapy was frequently inadequate for this population.
Abstract Background : The efficacy of non-carbapenems as an empirical antibiotic for extended-spectrum β-lactamases (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia in children remains controversial. We compared clinical and microbial outcomes according to the types of empirical antibiotics for treating pediatric patients with ESBL-producing E. coli and K. pneumoniae bacteremia. Methods : Data from pediatric patients aged ≤18 years who were hospitalized with monomicrobial ESBL-producing E. coli or K. pneumoniae bacteremia between January 2014 and May 2019 were analyzed retrospectively. The impact of empirical therapy was assessed as 30-day all-cause mortality and 2-day microbiological outcomes evaluated by sterility of blood cultures collected on day 2 after empirical antibiotic administration. Logistic regression analysis was used to control for the effects of confounding variables. Results : A total of 53 patients with bacteremia caused by ESBL-producing E. coli (n=29) and K. pneumoniae (n=24) were included in this study; the median age was 3.6 years, and all had underlying comorbidities. As empirical antibiotics, 27 patients were treated with meropenem, and non-carbapenem agents were administered to 26 patients; 84.6% (22/26) were converted to carbapenem antibiotics as the definitive antibiotic by day 2 after empirical antibiotic administration. Overall, the 30-day all-cause mortality of ESBL-producing E. coli and K. pneumoniae bacteremia was 17.0% (9/53). After adjustment, there was no statistically significant association of use of a non-carbapenem agent as an empirical antibiotic with microbiological failure at day 2 and 30-day all-cause mortality [adjusted odds ratio (OR), 1.0; 95% confidence interval (CI), 0.22–4.88, and adjusted OR, 0.1; 95% Cl, 0.01–1.56]. Conclusions : The empirical use of non-carbapenems might not be a risk factor for mortality and early microbiological outcomes in pediatric patients with ESBL-producing E. coli and K. pneumoniae BSI if early transition to appropriate antimicrobial therapy was possible.
Sign in to start a discussion.
More Papers Like This
Initial empirical antibiotics of non-carbapenems for ESBL-producing E. coli and K. pneumoniae bacteremia in children: a retrospective medical record review
Researchers reviewed medical records of children with bloodstream infections from antibiotic-resistant bacteria and found that starting with non-carbapenem antibiotics — a broader, less powerful class — did not increase mortality risk as long as treatment was quickly adjusted once lab results confirmed the specific bacteria involved.
Differential survival of potentially pathogenic, septicemia- and meningitis-causing E. coli across the wastewater treatment train
Researchers screened E. coli isolates from Canadian wastewater treatment plant effluents and found that 86 isolates carried virulence markers characteristic of extraintestinal pathogenic E. coli (ExPEC) strains capable of causing septicemia and meningitis. Many isolates belonged to pandemic lineages (ST131, ST95, ST73) and survived chlorination, indicating that conventional wastewater treatment does not adequately eliminate clinically important pathogenic E. coli.
Understanding the clinical and molecular epidemiological characteristics of carbapenem-resistant Acinetobacter baumannii infections within intensive care units of three teaching hospitals
Researchers analyzed carbapenem-resistant Acinetobacter baumannii (CRAB) — a dangerous antibiotic-resistant bacterium — in intensive care units across three hospitals and found it is common and growing increasingly resistant over time. Early identification and aggressive management are critical to stopping its spread in hospital settings.
Multidrug-resistant Escherichia coli causing diarrhea in yak calves on the Qinghai-Tibet Plateau: phenotypic characterization, whole-genome sequencing, and pathogenicity analysis
Scientists found dangerous, drug-resistant E. coli bacteria in sick yak calves in Tibet that doesn't respond to most common antibiotics. These "superbug" strains could potentially spread to humans through the food chain or environment, making infections much harder to treat. This highlights the growing global threat of antibiotic-resistant bacteria, especially in areas where antibiotics are used heavily in livestock.
Occurrence of EBSL and quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from poultry, domestic pigs and environment in the Msimbazi River Basin in Tanzania
Researchers investigated the occurrence and distribution of extended-spectrum beta-lactamase (ESBL) and plasmid-mediated quinolone resistance genes in multi-drug-resistant Escherichia coli and Klebsiella pneumoniae isolated from poultry, domestic pigs, and environmental samples in the Msimbazi River Basin, Tanzania. Screening 110 isolates for CTX-M, TEM, SHV, qnrA, qnrB, and qnrS genes revealed widespread resistance gene carriage across animal and environmental sources.